Page last updated: 2024-11-12
apidaecin ib
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
apidaecin: isolated from lymph fluid of honeybee; amino acid sequence given in first source; not antibiotic, since it does not come from microorganism [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 16142963 |
CHEMBL ID | 411529 |
MeSH ID | M0170179 |
Synonyms (6)
Synonym |
---|
CHEMBL411529 |
apidaecin |
apidaecin ib |
EX-A7434 |
123276-94-8 |
AKOS040732450 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (28)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID430937 | Membrane permeabilization in eukaryotic membrane model consisting of single unilamellar vesicle of L-alpha-phosphatidylcholine-cholesterol assessed as 5(6)-carboxyfluorescein release at high peptide-to-lipid ratio after 50 mins by fluorescence assay | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID430935 | Toxicity in human erythrocytes assessed as hemolytic activity at 300 uM after 60 mins | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID430925 | Chemical stability assessed as compound degradation at 2 mg/mL within 30 mins by HPLC and ESI-MS analysis in presence of trypsin | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID94138 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Klebsiella pneumoniae 22 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID9221 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID430936 | Membrane permeabilization in eukaryotic membrane model consisting of single unilamellar vesicle of L-alpha-phosphatidylcholine-cholesterol assessed as 5(6)-carboxyfluorescein release at high peptide-to-lipid ratio after 20 mins by fluorescence assay | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID198005 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 h of incubation at 37 C in Mueller-Hinton broth against Staphylococcus enteritidis PD1 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID64223 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli D22 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID197876 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Staphylococcus aureus G | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID64242 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli ML-35 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID482395 | Cytotoxicity against human SH-SY5Y cells at 600 ug/ml after 24 hrs by MTT assay | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens. |
AID430931 | Antimicrobial activity against Salmonella enteritidis D5 after 18 hrs by broth microdilution susceptibility test | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID430930 | Antimicrobial activity against Klebsiella pneumoniae 22 after 18 hrs by broth microdilution susceptibility test | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID430927 | Antimicrobial activity against Escherichia coli ML35 after 18 hrs by broth microdilution susceptibility test | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID430934 | Toxicity in human erythrocytes assessed as hemolytic activity at 30 uM after 60 mins | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID198329 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Salmonella Typhimurium ATCC 14028 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID64219 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli D21 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID430933 | Antimicrobial activity against Salmonella Typhimurium ATCC 14028 after 18 hrs by broth microdilution susceptibility test | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID430932 | Antimicrobial activity against Salmonella enteritidis PD1 after 18 hrs by broth microdilution susceptibility test | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID430928 | Antimicrobial activity against Escherichia coli O18K1H7 after 18 hrs by broth microdilution susceptibility test | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID482394 | Cytotoxicity against human HeLa cells at 600 ug/ml after 24 hrs by MTT assay | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens. |
AID198008 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Staphylococcus epidermidis 4 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID150919 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Pseudomonas aeruginosa ATCC 27853 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID94139 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Klebsiella pneumoniae 79 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID64216 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli ATCC 25922 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID198004 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Staphylococcus enteritidis D5 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID430929 | Antimicrobial activity against Escherichia coli ATCC 25922 after 18 hrs by broth microdilution susceptibility test | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. |
AID64243 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli O18:K1:H7 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (71)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (2.82) | 18.7374 |
1990's | 12 (16.90) | 18.2507 |
2000's | 13 (18.31) | 29.6817 |
2010's | 38 (53.52) | 24.3611 |
2020's | 6 (8.45) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.12
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.12) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 4 (5.56%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 68 (94.44%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |